EGFR和C-erbB2蛋白在非小细胞肺癌中的表达及其临床意义

目的　探讨EGFR和C erbB2蛋白与非小细胞肺癌 (NSCLC)的临床生物学行为及预后的关系。方法　采用免疫组化法观察 35例NSCLC患者及 7例非癌肺疾病患者组织标本中EGFR和C erbB2蛋白的表达。结果　EGFR和C erbB2蛋白在 35例NSCLC患者中过表达率分别为 6 5 .7%和 5 7.14 % ,且其过表达与NSCLC患者的TNM分期及淋巴结转移呈显著正相关 (P <0 .0 5 ) ,其中C erbB2蛋白过表达主要与肺腺癌患者的TNM分期及淋巴结转移呈显著正相关。EGFR或 /和C erbB2蛋白过表达的NSCLC患者生存期短、预后差 (P <0 .0 5 )。结论　EGFR和C erbB2蛋白过表达与NSCLC的发生、发展和转移密切相关 ,二者有协同作用 ,可作为评估NSCLC进展及判断预后的有价值的指标

Expression and clinical significance of epidermal growth factor receptor and C-erbB2 oncoprotein in non-small cell lung cancer

Objective To investigate the correlation of epidermal growth factor receptor (EGFR) and C erbB2 oncoprotein with clinical biological behavior and prognosis of non small cell lung cancer (NSCLC).Methods By immunohistochemical method,35 specimens of resected, paraffin embedded NSCLC and 7 cases of adjacent nonneoplastic lung tissues were examined for the expression of EGFR and C erbB2 oncoprotein.Results Of the 35 NSCLC cases, the overexpression rates of EGFR and C erbB2 oncoprotein were 65.7% and 57.14%, respectively. The overexpression of EGFR or C erbB2 oncoprotein was positively correlated with TNM stages and lymph node metastasis ( P < 0.05 ). The overexpression of C erbB2 oncoprotein was associated with TNM stages and nodal metastasis mainly in lung adenocarcinoma ( P < 0.05 ). The mean survival time was significantly shorter in patients with EGFR and/or C erbB2 positive expression than patients with EGFR and/or C erbB2 negative expression ( P < 0.05 ). Conclusion The overexpression of EGFR and C erbB2 oncoprotein is related to the clinical occurence, development and metastasis of NSCLC. EGFR and C erbB2 might be useful to determine prognosis and clinical strategies.